Showing results (1-10 of 92) with videos related to
Sort By:
Pageof 10
Polskie Archiwum Medycyny Wewnetrznej|April 11, 2003
[Antiphospholipid antibodies as risk factor for venous thromboembolism]Jerzy WindygaSeminars in Thrombosis and Hemostasis|April 21, 2016
Is Continuous Low-Dose Prophylaxis Superior to On-Demand Treatment for Patients with Hemophilia?Jerzy WindygaPolskie Archiwum Medycyny Wewnetrznej|November 23, 2007
[Acquired haemophilia]Anna Buczma, Jerzy WindygaPolish Archives of Internal Medicine|April 8, 2025
Antithrombotic therapy in patients with inherited bleeding disorders: practical considerationsJerzy Windyga, Riitta LassilaThrombosis Research|January 12, 2011
Clinical efficacy of a novel VWF-containing FVIII concentrate, Wilate(®), in the prophylaxis and treatment of bleeding episodes in previously treated haemophilia A patientsAnna Klukowska, Jerzy Windyga, Angelika BatorovaPolskie Archiwum Medycyny Wewnetrznej|March 19, 2005
[Hemophilia and other inherited blood coagulation disorders in Poland]Jerzy Windyga, Stanisław Lopaciuk, Ewa Stefańska, et al.Polskie Archiwum Medycyny Wewnetrznej|February 22, 2014
Practical aspects of new oral anticoagulant use in atrial fibrillationAnetta Undas, Tomasz Pasierski, Jerzy Windyga, et al.Przeglad Lekarski|March 11, 2011
[Application of mPCR and MLPA in diagnostics of alpha-thalassaemia]Anna Splitt, Urszula Mokras, Jerzy Windyga, et al.Expert Review of Hematology|May 17, 2014
BAX326 (recombinant coagulation factor IX) for the treatment and prophylaxis of hemophilia BJerzy Windyga, Brigitt E Abbuehl, Andrea E HafemanTherapeutic Advances in Hematology|October 18, 2014
BAX326 (RIXUBIS): a novel recombinant factor IX for the control and prevention of bleeding episodes in adults and children with hemophilia BJerzy Windyga, Maria Helena Solano Trujillo, Andrea E HafemanPageof 10